1. Impact of severe‐to‐very severe chronic obstructive pulmonary disease on the prognosis of patients with non‐small cell lung cancer who received chemotherapy.
- Author
-
Dong, Weigang, Zhu, Yaqian, Du, Yan, Wang, Lina, Feng, Xue, and Ma, Shuping
- Subjects
- *
OBSTRUCTIVE lung diseases , *NON-small-cell lung carcinoma , *PROGNOSIS - Abstract
Introduction: Chronic obstructive pulmonary disease (COPD) is associated with poor prognosis in non‐small cell lung cancer (NSCLC) patients. There are limited data about the impact of severe‐to‐very severe COPD on prognosis in patients with NSCLC receiving first‐line chemotherapy. Objectives: To investigate whether severe‐to‐very severe COPD impacted survival of patients with NSCLC receiving first‐line chemotherapy. Methods: A retrospective review was performed on 513 consecutive NSCLC patients receiving first‐line chemotherapy between February 2014 and May 2018. Prognostic impact of severe‐to‐very severe COPD was analysed using regression analyses. Results: Totally 258 NSCLC patients (118 non‐COPD, 96 mild‐to‐moderate COPD and 44 severe‐to‐very severe COPD) were evaluated retrospectively. Kaplan‐Meier analysis showed that the median overall survival times in the severe‐to‐very severe COPD, mild‐to‐moderate COPD and non‐COPD groups were 14.0 months [95% confidence interval (CI): 11.0‐17.0], 18 months (95% CI: 14.8‐21.2) and 19 months (95% CI: 15.3‐22.7), respectively. The difference was significant between patients with severe‐to‐very severe COPD and those without COPD (χ2 = 6.8, P = 0.009) and between patients with severe‐to‐very severe COPD and those with mild‐to‐moderate COPD (χ2 = 4.0, P = 0.045). Multivariate analysis showed that survival time was significantly shorter in the severe‐to‐very severe COPD group than in the non‐COPD group (adjusted hazard ratio: 1.876, 95% CI: 1.161‐3.030, P = 0.01) and mild‐to‐moderate COPD group (adjusted hazard ratio: 1.782, 95% CI: 1.046‐3.034, P = 0.033). Conclusion: Severe‐to‐very severe COPD may worsen the prognosis of NSCLC patients who received first‐line chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF